Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder
Annals of Neurology · 2026-04 · 99 (4) · 912-921
DOI: 10.1002/ana.78109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 28.11.2025. Verfasst von Shijun Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: tau Proteins, Cognitive Dysfunction, REM Sleep Behavior Disorder. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI MRC Senior Clinical Fellowship (MR/V007068/1) to GKT, Michael J Fox Foundation to GKT, Hilary and Galen Weston Foundation to GKT.
Abstract (Originalsprache)
Objective
Assess the performance of serum phosphorylated tau 217 (p‐tau217) and neurofilament light chain (NfL) in predicting risk of cognitive impairment or phenoconversion to dementia in individuals with iRBD.
Methods
We measured serum p‐tau217 and NfL levels by electrochemiluminescence across 4 polysomnographically confirmed iRBD cohorts (n = 300), including individuals who phenoconverted to Parkinson's disease (PD) (n = 51), dementia with Lewy bodies (DLB) (n = 22), and multiple system atrophy (MSA) (n = 5).
Results
Serum p‐tau217 levels were increased in individuals with iRBD and cognitive impairment (CI) on testing defined as Montreal Cognitive Assessment
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
- Population Health Sciences, University of Bristol, Bristol, UK.
- Institute for Neurodegenerative Disorders, New Haven, CT.
- German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany.
- Centre of Neurology, Department of Parkinson, Sleep and Movement Disorders, University of Bonn, Bonn, Germany.
ORCID-Profile: Wolfgang Oertel, George K Tofaris
Förderung
- UKRI MRC Senior Clinical Fellowship (MR/V007068/1) to GKT
- Michael J Fox Foundation to GKT
- Hilary and Galen Weston Foundation to GKT
- UKRI MRC DPFS (MR/Y019415/1) to GKT
- NIHR Oxford Biomedical Research Centre to GKT and MH
- Else Kröner-Fresenius-Stiftung
- Köln Fortune Program, Faculty of Medicine, University of Cologne
- Ministry of Culture and Science of the State of North Rhine Westphalia
Zitieren
APA
Yan, S., Sahoo, A., Zerenner, T., Marek, K., Sommerauer, M., Oertel, W., Hu, M. T., & Tofaris, G. K. (2026). Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder. Annals of Neurology, 99(4), 912-921. https://doi.org/10.1002/ana.78109
Vancouver
Yan S, Sahoo A, Zerenner T, Marek K, Sommerauer M, Oertel W, et al. Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder. Annals of Neurology. 2026;99(4):912-921. doi:10.1002/ana.78109
BibTeX
@article{Yan2026,
author = {Yan, Shijun and Sahoo, Anis and Zerenner, Tanja and Marek, Kenneth and Sommerauer, Michael and Oertel, Wolfgang and Hu, Michele T and Tofaris, George K},
title = {Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder},
journal = {Annals of Neurology},
year = {2026},
volume = {99},
number = {4},
pages = {912--921},
doi = {10.1002/ana.78109}
}
EUVIMED